If you experience dose-increase side effects during this phase (nausea returning temporarily after stepping up from 0.25 mg to 0.5 mg, for example), temporarily revert to Phase 1 eating strategies for three to five days until your body adjusts
Rs 5,500 / VialGet Latest Price Product Details: Bremelanotide (PT-141) is an FDA-approved, centrally acting peptide used primarily to treat hypoactive sexual desire disorder (HSDD) in premenopausal women and, off-label, for erectile dysfunction/low libido in men
Wegovy (Novo Nordisk) Patient Support Program Eligibility: Must have private insurance that covers Wegovy, not receiving government drug benefits Savings: Up to $150 per monthly prescription for 12 months Maximum annual benefit: $1,800 How it works: Reduces out-of-pocket costs after insurance pays their portion Saxenda (Novo Nordisk) Patient Support Program Eligibility: Private insurance covering Saxenda, not on provincial drug plans Savings: Up to $120 per monthly prescription Maximum annual benefit: $1,440 How it works: Applied at pharmacy, reduces copay amount Expected Retatrutide Program (Not Yet Announced) Projected eligibility: Private insurance with Retatrutide coverage, not receiving provincial benefits Projected savings: $200-300 per monthly prescription based on medication cost Projected maximum benefit: $2,400-3,600 annually Expected launch: Same time as Health Canada approval The catch with Canadian savings programs: you need private insurance that already covers the medication
Supports Fat Metabolism L-Carnitine is widely associated with fatty acid transport in the body
In all, there are currently 45 GLP-1/GIP drugs intended for obesity in the pipeline
